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Hypothalamus is a key area involved in the control of metabolism and food intake
via the integrations of numerous signals (hormones, neurotransmitters, metabolites)
from various origins. These factors modify hypothalamic neurons activity and generate
adequate molecular and behavioral responses to control energy balance. In this complex
integrative system, a new concept has been developed in recent years, that includes
reactive oxygen species (ROS) as a critical player in energy balance. ROS are known to
act in many signaling pathways in different peripheral organs, but also in hypothalamus
where they regulate food intake and metabolism by acting on different types of neurons,
including proopiomelanocortin (POMC) and agouti-related protein (AgRP)/neuropeptide
Y (NPY) neurons. Hypothalamic ROS release is under the influence of different factors
such as pancreatic and gut hormones, adipokines (leptin, apelin,...), neurotransmitters
and nutrients (glucose, lipids,...). The sources of ROS production are multiple including
NADPH oxidase, but also the mitochondria which is considered as the main ROS producer
in the brain. ROS are considered as signaling molecules, but conversely impairment of this
neuronal signaling ROS pathway contributes to alterations of autonomic nervous system
and neuroendocrine function, leading to metabolic diseases such as obesity and type
2 diabetes. In this review we focus our attention on factors that are able to modulate
hypothalamic ROS release in order to control food intake and energy metabolism, and
whose deregulations could participate to the development of pathological conditions. This
novel insight reveals an original mechanism in the hypothalamus that controls energy
balance and identify hypothalamic ROS signaling as a potential therapeutic strategy to
treat metabolic disorders.
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INTRODUCTION
The role of the brain in the control of energy homeostasis has
been suggested at the middle of the nineteenth century by Claude
Bernard whowas the first to evoke its importance with the famous
experiment “la piqûre diabétique” (Bernard, 1849). Indeed, he
observed an important rise of glycemia after a stimulation of the
floor of the fourth ventricle. In 1953, Gordon Kennedy identi-
fied the precise brain area involved in this phenomenon. He has
demonstrated that circulating factors released by the adipose tis-
sue could reach the hypothalamus in order to modulate food
intake and energy expenditure, and thus regulate body weight
(Kennedy, 1953). Moreover, the medio-basal hypothalamus is
a privileged central area which directly senses various factors
(hormones, metabolites). In fact, at the close proximity of the
arcuate nucleus (ARC), themedian eminence is a circumventricu-
lar organ that presents a blood-brain barrier-free area that allows
peripheral factors to inform hypothalamic structures about the
energy status (Rodriguez et al., 2010). Since 1940, the develop-
ment of stereotaxic methods in animals has offered researchers
the opportunity to practice stimulation or localized destructions
of various hypothalamic nuclei, and then identified their precise
role (Brobeck, 1946).
The first neurons in contact with peripheral signals are called
“neurons of first order.” These neurons are only present in the
ARC (Cone et al., 2001) and a lesion of this hypothalamic region
induces hyperphagia and obesity (Olney, 1969). It is largely well
described in the literature that the ARC presents two subsets of
neurons that have opposite effects on feeding. One of these group
of neurons express pro-opiomelanocortin (POMC) and cocaine-
amphetamine-regulated transcript (CART), and upon stimula-
tion, these neurons produce anorectic effects (Cone, 2005). The
POMC precursor is cleaved into α-melanocyte-stimulating hor-
mones (α-MSH) which reduces food intake, body weight and
increases energy expenditure (Kim et al., 2000; Yasuda et al.,
2004). The second group of neurons in the ARC leads to orex-
igenic responses upon activation. These neurons express neu-
ropeptide Y (NPY) and the agouti-gene-related transcript (AgRP)
(Clark et al., 1984; Rossi et al., 1998) which stimulate food
intake and reduce energy expenditure (Fekete et al., 2002). In
genetically-modified obese rodents, as well as in fasted normal
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animals, NPY mRNA expression and protein content are ele-
vated in ARC (Sanacora et al., 1990; Wilding et al., 1993; Park
et al., 2004). Collectively, this suggests that (1) over-activation
or dysfunction of NPY neurons is involved in the emergence of
metabolic diseases, but also that (2) NPY neurons can inhibit
melanocortin system. Interestingly, subsets of POMC neurons
contain both gamma amino butyric acid (GABA) and glutamate
(Dicken et al., 2012). Subsets of NPY neurons also contain GABA
(Horvath et al., 1997) and GABA from NPY neurons participates
to inhibition of POMC neurons. This unidirectional input from
the NPY to POMC cells brings to light one anatomical basis of
energy regulation. This neuronal interaction seems to favor the
tonic inhibition of satiety signal, and also promotes feeding or
over-feeding when food is available in excess. This finding rein-
forces the key role of an intact melanocortin system in the control
of energy balance.
The POMC and NPY/AgRP neurons of the ARC interact with
various brain regions that include hypothalamic areas such as
ventromedial hypothalamus (VMH), dorsomedial hypothalamus
(DMH), paraventricular nucleus (PVN) and lateral hypothala-
mus (LH) (Wynne et al., 2005). Lesion studies in rodent have
shown that ablation of VMH, DMH or PVN results in hyper-
phagia and obesity (Leibowitz et al., 1981; Shimizu et al., 1987;
Bellinger and Bernardis, 2002) whereas lesions in the LH lead
to hypophagia (Bernardis and Bellinger, 1993). To summarize, a
proposal of dual-center model has been proposed that identifies
the VMH as the “satiety center” and the LH as the “hunger center”
(Stellar, 1994).
These hypothalamic nuclei have the ability to sense the level
of available fuel energy in the body. This detection of peripheral
signals involves various molecular actors such as classical neu-
rotransmitters but also “non-classical” diffusible molecules such
as reactive nitrogen species (RNS) and reactive oxygen species
(ROS). To this aim, nitric oxide (NO) is an atypical molecular
actor which belongs to RNS family, but could also be associated
to ROS family since it is a radical gas derived from nitric and oxy-
gen. NO has a very short half-life and can largely diffuse in cells
(Palmer et al., 1987). It has a single electron, allowing numer-
ous interactions with cellular components. In the brain, chemical
properties of NO permits its diffusion across hypothalamic cells
to control neurotransmitter release (Ohkuma and Katsura, 2001),
but also synaptic plasticity (Shibuki and Okada, 1991), that leads
to the modulation of food intake (Morley and Flood, 1991) and
glucose metabolism (Duparc et al., 2011a). In addition to RNS,
recent data argue that differential fuel utilization in response to
nutrients is linked to ROS formation. This ROS generation is not
merely a “byproduct” of substrate oxidation, but has a crucial role
in regulating neuronal response in a substrate-dependentmanner.
In this review, we will describe the molecular mechanisms gen-
erating ROS in response to metabolic signals, in order to control
metabolism and food intake. In physiological conditions, ROS
production is considered as a signaling actor produced at low level
and in a transient manner. On the other hand, over-production
of ROS, associated to a dysfunction of ROS buffering systems,
can lead to the development of chronic diseases. Thus, central
chronic ROS release participates in the establishment of numer-
ous diseases such as type 2 diabetes (T2D), but also in cancer
and neurodegenerative disorders (as Parkinson and Alzheimer
disease).
ROS PRODUCTION: FOCUS ON NEURONAL CELLS
INTRODUCTION
ROS are radical species derived from oxygen of which the most
known are the superoxide anion (O−2 ), the hydrogen peroxide
(H2O2) and the hydroxyl radical (OH−). These “free-radical”
ROS have unpaired electrons on an oxygen atom. This prop-
erty makes ROS very unstable as they react quickly with others
surrounding chemical molecules in order to pair their electrons.
These radical reactions often lead to a new radical formation gen-
erating a chain reaction, and thus activate numerous signaling
pathways (Gutteridge and Halliwell, 2000).
Within the cell, all processes using oxygen may produce ROS.
However, the mitochondrial transport electron chain is a major
source of ROS generation in physiological conditions (Bashan
et al., 2009). ROS are also produced by the NADPH oxidases
(NOX) which are membrane-bound enzymatic complexes able to
transfer electrons from cytosolic NADPH to oxygen (Lambeth,
2004; Hordijk, 2006). Finally, another source of ROS is the
endoplasmic reticulum (ER) (Cross and Jones, 1991) and the
peroxisome (Schrader and Fahimi, 2006).
In order to limit ROS concentration, cells are equipped
with various enzymatic and non-enzymatic antioxidant systems.
Several enzymes directly degrade ROS such as the superoxide
dismutase (SOD), the catalase and the glutathione peroxidase
(Turrens, 2003). Various non-enzymatic scavengers can also sup-
port detoxification of free radicals. The majority are lipophilic
(vitamin E, ubiquinone or coenzyme Q, and carotenoids) or
hydrophilic (vitamin C, glutathione) (Clark, 2002).
When ROS are moderately and transiently produced, they
are able to reversibly modify some surrounding targets and act
as “signal” molecules (Droge, 2002). However, when oxidants-
antioxidants balance is altered, due to an excessive production
of ROS and/or a decrease in antioxidant systems, and is asso-
ciated to the expansion of oxidative stress (Droge, 2002), ROS
become toxic to the cell, and could be involved in the develop-
ment of specific diseases markers such as insulin resistance and
type 2 diabetes (Bashan et al., 2009).
ROS AND NEURONS
ROS are also strongly present in the brain. The large majority of
ROS produced by neurons have amitochondrial origin (Bao et al.,
2009). However, localization of NOX in different regions of the
central nervous system have been determined by immunohisto-
chemical approaches in rats (Kim et al., 2005) and mice (Serrano
et al., 2003). Indeed, NOX are present in hippocampus, cortex,
amygdala, striatum, thalamus and hypothalamus.
ROS can act directly on the brain to control many central
functions. Neurons can sense, transmit and convert ROS sig-
nals into appropriate intracellular responses, including synaptic
plasticity. For example, NOX activity in the hippocampus is
required to induce normal cellular process in these neurons, such
as long-term potentiation (a form of activity-dependent synap-
tic plasticity) and hippocampus-dependent memory (Infanger
et al., 2006). ROS production by mitochondria also occurs in the
Frontiers in Neuroscience | Neuroendocrine Science February 2015 | Volume 9 | Article 56 | 2
Drougard et al. Hypothalamic ROS and metabolic disorders
hypothalamus, and NOX subunits are also present in the ARC,
VMN, and PVN (Infanger et al., 2006). Hypothalamus is a key
area involved in control of glucose homeostasis (Knauf et al.,
2013). Indeed, a population of specialized hypothalamic neurons
is identified as gluco-sensors (Oomura et al., 1964). These neu-
rons are classified into two categories, which differ both by their
mode of action and by their precise localization, i.e., neurons
excited by glucose (named glucose-excited or GE) and neurons
inhibited by glucose (named glucose-inhibited or GI). Raising
plasma glucose level after a largemeal results in an increased brain
level to 4,5mM and an increase in brain glucose activates GE neu-
rons, while GI remain inactive (Routh, 2002). At the opposite,
during a period of fasting, reduction in the concentration of brain
glucose inhibits GE neurons and activates GI ones (Routh, 2010).
Although KATP channels seem to be essential for the function
of gluco-sensors, several studies show a depolarization of these
neurons via KATP channels independent mechanisms (Ainscow
et al., 2002; Fioramonti et al., 2004). Among these mechanisms,
mitochondrial ROS (mROS) are clearly involved in hypothala-
mic glucose sensing (Leloup et al., 2006). Indeed, a transient
increase of glucose stimulates mROS generation on hypothalamic
slices ex vivo. In addition, intra-carotid glucose load (therefore
only detectable by the hypothalamus) in rats triggers a signifi-
cant increase of ARC neuronal activity (Leloup et al., 2006) which
is abolished by a co-injection of the antioxidant enzyme cata-
lase. These results demonstrate that hypothalamic glucose sensing
requires the acute generation of ROS as signaling molecules to
induce a neuronal response.
Strong evidences demonstrate that ROS action in the brain can
affect most of the peripheral tissues via the Autonomous Nervous
System (ANS). For example, Zimmerman et al., observed
that O−2 was necessary to elicit vasopressor and bradycardiac
responses produced by intracerebroventricular (icv) administra-
tion of Angiotensin-II (Ang-II) in mice. Indeed, scavenging O−2
in brain completely abolished cardiovascular actions of Ang-II
(Zimmerman et al., 2002). Moreover, central administration of a
SOD mimetic attenuates the increase in renal sympathetic nerve
activity, norepinephrine release and blood pressure induced by icv
injection of Ang-II (Campese et al., 2004, 2005; Lu et al., 2004).
Therefore, ROS in the brain are of crucial importance to provide
signals in periphery via autonomous nervous system.
Thus, ROS have a strong role as signaling molecules in the
central nervous system, and more particularly in the hypotha-
lamus. Since hypothalamus is a key area involved in the control
of energy homeostasis, we are now going to focus on the role of
hypothalamic ROS in the regulation of energy metabolism and
food intake.
INVOLVEMENT OF HYPOTHALAMIC ROS IN THE CONTROL
OF METABOLISM AND FOOD INTAKE
We have previously discussed that a physiological increase of
ROS levels has a signaling role in the hypothalamus. This brain
area receives signals from the periphery such as nutrients (glu-
cose and lipids) and hormones, which in turn are able to
modulate the activity of hypothalamic neurons. This effect on
hypothalamic neurons, including POMC and NPY/AgRP neu-
rons, further impact peripheral fuel metabolism via the ANS or
neuroendocrine mediators. Here, we will describe the effect of
nutrient action (such as glucose and lipids) and hormones on
hypothalamic ROS release, associated with peripheral metabolic
regulation and food intake.
NUTRIENTS
Glucose and lipids are directly detected by hypothalamic neurons
in order to implement the adaptive response for the metabolism.
An intracarotid injection of glucose, which targets specifically
the hypothalamus, generates a transient release of hypothala-
mic ROS (Leloup et al., 2006). This release of hypothalamic
ROS induces, via the parasympathetic nervous system outflow,
a peak of insulin 1–3min later with no change in peripheral
blood glucose. Scavenging ROS generation in the brain by the use
of antioxidant molecules significantly disturbs insulin secretion
induced by the cerebral glucose load, demonstrating the key role
of hypothalamic ROS in the control of energy metabolism. In this
experimental model, ROS production involved in glucose sensing
has a mitochondrial origin. In fact, glucose co-injected with the
mitochondrial uncoupler CCCP decreases significantly the peak
of insulin (Leloup et al., 2006). If we focus on food intake, a
VMH glucose infusion attenuates the increase of food intake after
refeeding following an overnight fast, via a mechanism dependent
on hypothalamic mROS production (Carneiro et al., 2012).
Concerning lipids, the literature also showed that these cir-
culating nutrients can directly act as signaling molecules in the
hypothalamus (Lam et al., 2005). A provoked acute hypertriglyc-
eridemia in rats generates an acute ROS production in the VMH
30min after an intraperitoneal injection of lipids (Benani et al.,
2007). This hypothalamic ROS release is local, rapid and transient
since it returns to basal levels within 4 h after injection. Therefore,
this hypothalamic ROS modulation is able to inhibit food intake
only 1 h after lipid injection. This anorectic effect is directly
attributable to hypothalamic ROS release since icv infusion of
antioxidant drugs, such as glutathion and trolox (an analog of
vitamin E), abolishes the decrease of food intake. Similarly to
glucose, lipids generate hypothalamic mitochondrial ROS pro-
duction concomitant to an increase in mitochondrial respiration
(Benani et al., 2007).
We described above that glucose and lipids generate
hypothalamic ROS release through an action on mitochondria.
Mitochondrial morphology is associated with mROS produc-
tion and energy status (Yoon et al., 2011). Mitochondria are
dynamic organelles that continuously change their structures
under the control of different sets of proteins through fission
and fusion mechanisms. A recent study has demonstrated that,
in AgRP neurons, changes of mitochondrial morphology (size
and number) are associated with the metabolic state of these
neurons (Dietrich et al., 2013). Indeed, food deprivation dur-
ing 24 h leads to an increase in mitochondria density and a
decrease in mitochondria size in AgRP neurons, which are char-
acteristic of changes in mitochondria dynamic toward fission,
while neighboring anorexic POMC neurons display a decrease
in mitochondria density. Conversely, high-fat-diet feeding (HFD)
(i.e., positive energy balance) leads to mitochondrial fusion in
AgRP neurons. These changes were cell-type specific because
this phenomenon did not occur in POMC neurons. The fission
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machinery involves dynamin-related protein 1 (DRP1), which
is translocated to the mitochondrial membrane where it forms
a contractile “ring” involved in the division of mitochondria.
Under basal conditions, DRP1 is cytoplasmic. In response to an
intracarotid glucose bolus injection, DRP1 level is increased in
mitochondria from VMH extract 1min post-injection, and cor-
relates with hypothalamic mROS production (Carneiro et al.,
2012). These results indicate that mitochondrial fission is neces-
sary for the induction of hypothalamic mROS release in response
to glucose. Inhibition of DRP1 recruitment in the VMH mito-
chondria using siRNA is deleterious by the loss of hypothalamic
mROS signaling, insulin release and the satiating effect of glucose.
On the other hand, fusion machinery involves mitofusins (Mfn 1
andMfn2). AgRP-specificMfn1 orMfn2 knock-outmice gain less
weight when fed with a HFD (Dietrich et al., 2013). Interestingly,
these changes in fusion-like mitochondrial dynamics are neuron-
type specific because POMC-specificMfn2 knockoutmice exhibit
hyperphagia, an increase in body weight and a decrease in energy
expenditure (Schneeberger et al., 2013). In this mouse model, it
is noteworthy that the number of mitochondria-ER contacts was
significantly reduced in POMC neurons. This result indicates a
synergy of action between hypothalamic RE and mitochondria
in metabolic control. The change in mitochondrial dynamics in
hypothalamic neurons directly affects distal metabolic organs and
suggests a key role of mROS.
Other key molecular actors of mitochondrial function are
uncoupling proteins (UCP) which are mitochondrial inner mem-
brane proteins promoting proton leak (Aquila et al., 1985). These
proteins control mROS release and specifically UCP2 which was
described as a negative regulator of mitochondrial hydrogen per-
oxide production (Negre-Salvayre et al., 1997). Besides allowing
protons to transit from the matrix to the inter-membrane space
of the mitochondria, it has been suggested that UCP2 allows the
transport of metabolites such as aspartate, malate and oxaloac-
etate. As such, UCP2 could reduce substrates of Krebs cycle,
decrease electrons transport chain activity and also attenuates
ROS production (Vozza et al., 2014). UCP2 is highly expressed
in the hypothalamus (Richard et al., 1998), and more precisely in
both POMC andNPY/AgRP neurons. This mitochondrial protein
is strongly linked to nutritional status because the hypothala-
mic mRNA and protein expression of UCP2 is increased during
the fasted state (Coppola et al., 2007). A hypothesis developed
by Andrews et al., suggests that during negative energy balance
(such as fasting or before a meal), NPY/AgRP neurons are acti-
vated via a decrease in basal mROS production, probably because
of the activation of UCP2 (Andrews et al., 2008). Conversely,
mROS levels in POMC neurons are also reduced, but these neu-
rons are silent. In contrast, during positive energy balance, mROS
are able to accumulate in POMC neurons to inhibit food intake.
As expected, genetic inactivation of UCP2 attenuates the refeed-
ing signal, due to an uncontrolled increase of ROS in NPY/AgRP
neurons that lead to decrease their activities. These results under-
score the importance of the level of ROS released, depending on
the type of neurons.
As previously described, changes in glucose levels are sensed
in the brain by GE and GI neurons. Arcuate nucleus POMC
neurons are considered as GE while AgRP/NPY neurons are GI.
Parton et al., have demonstrated the essential role of glucose sens-
ing by POMC neurons in the overall physiological control of
blood glucose (Parton et al., 2007). Specific genetic deletion of
Kir6.2 subunit in KATP channels, required for glucose detection in
POMC neurons, impairs the whole-body response to a systemic
glucose load. In the same study, the authors demonstrated that
UCP2 negatively regulates glucose sensing in POMC neurons. By
using genipin (an UCP2 inhibitor) or UCP2 knock-out mice, they
have induced an increase in POMC neurons firing rate. Glucose
sensing by POMC neurons became defective in obese mice fed a
HFD, suggesting that loss of glucose sensing has a causal role in
the development of type 2 diabetes.
Thus, it appears that NPY/AgRP neurons activation is medi-
ated by a decrease in ROS levels while POMC neurons activation
is driven by ROS (Andrews et al., 2008). Indeed, icv admin-
istration of ROS scavengers induces significantly lower c-Fos
expression in POMC neurons and increases food intake dur-
ing light cycle, observed via an increase of c-Fos expression in
AgRP/NPY neurons (Diano et al., 2011). Similarly, addition of
H2O2 depolarizes POMC neurons, increases the firing rate, and
an icv injection of H2O2 causes significantly less feeding of mice
after an overnight fast.
From a molecular perspective, POMC neurons seem to use
glucose as their main fuel since their firing rate vary as a func-
tion of in glucose concentrations (Ibrahim et al., 2003). On the
other hand, NPY/AgRP neurons are inhibited by high levels of
glucose and may use free fatty acids as their main fuel (Mountjoy
et al., 2007; Andrews et al., 2008). This differential fuel utilization
underlies the presence of two distinct and competitive mecha-
nisms in these neuronal populations: glycolysis and β-oxidation.
When glycolysis is elevated, end-product derived from this reac-
tion inhibit β-oxidation, and conversely, when β-oxidation is
increased, glycolysis is inhibited. Both systems are opposite and
produce ROS. An increase in the activity of NPY/AgRP neu-
rons is followed by Ca2+ influx, which was demonstrated to
elevate ROS production in neurons (Hernandez-Fonseca et al.,
2008). However, NPY/AgRP neurons do not produce consider-
able amount of ROS, indicating that these neurons have cellu-
lar properties associated with low capacity for ROS production
and/or high capacity to buffer ROS. These opposite effects of
ROS release in POMC and NPY/AgRP neurons, that contribute
to nutrient sensing and appetite regulation, have been demon-
strated by the work of Kuo et al., By using an appetite-suppressing
sympathomimetic agent, phenylpropranolamine (PPA), authors
have shown the involvement of Protein Kinase C (PKC) in the
generation of hypothalamic ROS which stimulates POMC neu-
rons activity and inhibits NPY neurons (Kuo et al., 2011). Central
inhibition of ROS production by icv infusion of glutathione atten-
uates PPA anorectic effect together with the icv injection of PKC
oligonucleotide antisense. In a similar study, the same authors
demonstrated that hypothalamic NF-kB signaling is also involved
in decrease of food intake by PPA treatment. This anorectic effect
is mediated by the decrease of NPY expression and the rise of the
expression of endogenous antioxidants such as SOD or glutha-
tione peroxidase, demonstrating the impact of ROS (Kuo et al.,
2012). Another essential actor which participate to the regula-
tion of ROS production is Ca2+. Voltage-gated Ca2+ channels
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are expressed throughout the entire hypothalamus contributing
to the increase of cytoplasmic Ca2+ levels in sensitive neurons
(Marques-Da-Silva and Gutierrez-Merino, 2012). The mainte-
nance of intracellular Ca2+ homeostasis depends on (1) the pre-
cise control of Ca2+-ATPases activity in the plasma membrane,
(2) the Ca2+ uptake into intracellular compartments, (3) the
influx through voltage-operated channels and 4) the effectiveness
of Ca2+ buffering via Calcium Binding Proteins (CBPs) (Strehler
et al., 2007; Nicholls, 2009). Excessive intracellular Ca2+ accu-
mulation causes mitochondrial ROS production (Weber et al.,
2010) and hypothalamic CBPs such as Secretagogin (Scgn) mod-
ulate this ROS release by buffering Ca2+(Gyengesi et al., 2012).
Thus, Scgn which is widely expressed in the NPY/AgRP neu-
rons (Gyengesi et al., 2013) from the ARC but not in POMC
neurons, could explain the lower production of ROS by these
neurons. There seems to be a direct requirement to buffer Ca2+
in NPY but not in POMC neurons, to maintain cellular firing
rate. Thus, buffering Ca2+ controls ROS production and allows
the modulation of neurons as a function of the nutritional state
(Figure 1).
All these actors involved in transient ROS production in
response to nutrients, clearly demonstrate a key role of ROS sig-
naling as a real gauge of energy status, which induces a fine tuning
control of energy metabolism and food intake.
HORMONES
Like nutrients, hormones which are key signals of the metabolic
state of organs, must be detected by the hypothalamus to con-
trol energy homeostasis. We will now discuss the role of the
orexigenic hormone ghrelin and of two anorectic hormones lep-
tin and insulin. These hormones reach the hypothalamus, have
their receptors on hypothalamic POMC and NPY/AgRP neurons
and are clearly involved in the control of food intake and energy
metabolism via signaling pathways involving ROS release.
Ghrelin
Ghrelin is a gut-derived hormone secreted into the bloodstream
which activates NPY/AgRP neurons and increases food intake
(Andrews, 2011). Levels of this hormone rise during the fasting
state, making a signal of starvation for neurons. Ghrelin receptor
(GHSR), a seven trans-membrane G-coupled protein linked to
Gq, is predominantly expressed in NPY/AgRP neurons (Willesen
et al., 1999). In response to intraperitoneal injection of ghre-
lin, the number of mitochondria in NPY neuronal perikarya is
increased in a UCP2-dependent manner while POMC perikarya
remains unaffected (Andrews et al., 2008). In the same way, ghre-
lin induces symmetric, putatively inhibitory synapses on POMC
neurons correlated with recruitment of miniature inhibitory
post-synaptic currents (mIPSCs) on these cells. Conversely, ghre-
lin significantly reduces the number of asymmetric, putatively
excitatory synapses on POMC neurons. This synaptic plasticity
demonstrates how ghrelin hyperpolarizes POMCneurons by acti-
vating inhibitory NPY/AgRP (especially GABAergic) inputs. In
parallel, ghrelin increases UCP2 expression, which scavenges free
radicals in NPY neurons without affecting ROS production in
POMC neurons. All these effects previously described are linked
to the decrease in ROS levels in NPY/AgRP via UCP2 since the
effect of ghrelin is totally lost in UCP2 knock-out mice. The scav-
enging of ROS by icv infusion of a cocktail of antioxidants in
UCP2 knock-out mice restores the action of ghrelin demonstrat-
ing the key role of hypothalamic ROS in ghrelin effects (Andrews
et al., 2008).
From a molecular perspective, ghrelin activates AMPK in NPY
neurons, which importantly raises mitochondrial respiration and
ROS production (Andrews et al., 2008). Via the activation of
GHSR on NPY neurons, ghrelin generates an increase in intra-
cellular Ca2+ levels. Indeed, ghrelin induces a presynaptic sig-
naling pathway that induces direct Ca2+ release from internal
stores in NPY/AGRP neurons (Yang et al., 2011) and also acti-
vates Calmodulin-dependent protein Kinase Kinase (CaMKK)
(Cummings et al., 2005). Activated CaMKK induces AMPK acti-
vation which generates ATP and fatty acid oxidation that might
contribute to the neuron-specific activation of fatty acid oxida-
tion and the resulting buffering of ROS (Horvath et al., 2009).
CaMKK is particularly involved in the hypothalamic control
of appetite because its deletion in NPY/AgRP neurons reduces
food intake and body weight, while deleting CaMKK in POMC
neurons does not affect energy homeostasis (Anderson et al.,
2008; Gyengesi et al., 2012). Systemic injection of ghrelin fails
to induce food intake in CamKK knock-out mice, demonstrating
that CaMKK is also involved in the effect of ghrelin (Anderson
et al., 2008). This synergy of effects between ROS and Ca2+ is
necessary to generate signaling pathways in NPY/AgRP neurons
which is involved in the action of ghrelin on food intake. Precise
mechanisms need to be determined.
Finally, it is also known that motivation is an essential part
of food intake, involving reward system and memory, which are
regulated by dopamine neurons. Ghrelin has been shown to play
a role for incentive value of food cue by controlling the activ-
ity of dopamine neurons (Abizaid et al., 2006; Andrews et al.,
2006). Similar to its effect on NPY/AgRP neurons, ghrelin acti-
vates dopamine neurons in an UCP2-dependent manner and via
a decrease of ROS production. Indeed, UCP2 knock-out mice
exhibit a reduced dopamine turnover (Andrews et al., 2006).
Besides its direct effect on the dopamine reward system, ghrelin
regulates dopamine neurons directly via activation of AgRP neu-
rons and inhibition of PVN, which induces food seeking behavior
(Krashes et al., 2011; Atasoy et al., 2012).
Leptin
Leptin is an adipose tissue derived hormone (i.e., adipokine)
which plays a central role in the regulation of energy homeosta-
sis. Leptin acts on both NPY/AgRP and POMC neurons through
its receptor LepRb (Morton and Schwartz, 2011). Leptin reaches
hypothalamus and increases the activity of POMC neurons. This
effect on POMC neurons induces a decrease in food intake and
a rise in energy expenditure via the action of sympathetic ner-
vous system on Brown Adipose Tissue (BAT) and muscles. Unlike
ghrelin which modulates ROS levels in NPY/AgRP neurons, lep-
tin seems to induce ROS levels in POMC neurons (Diano et al.,
2011). Indeed, by using dihydroethidium (DHE; a substrate for
fluorimetric detection of peroxidase as a readout of ROS), Diano
et al., have demonstrated the lowest level of ROS in POMC neu-
rons of leptin knock-out mice (ob/ob). In contrast, a 48 h leptin
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FIGURE 1 | POMC and NPY/AgRP activation via ROS release in
function of nutritional state. POMC and NPY/AgRP neurons generate
opposing effects on food intake and metabolism. In the fed state, glucose,
lipids, insulin, and leptin actions lead to ROS release in both type of
neurons, for instance via a rise of Ca2+ concentration and mitochondrial
dynamics. This transient increase in intracellular ROS stimulates POMC
neurons activity and inhibits NPY/AgRP neurons, engendering decrease in
food intake and increased energy expenditure. In the fasted state,
NPY/AgRP neurons become more active, via an increase in Calcium
Binding Proteins (CBPs) and UCP2 expression that respectively buffer
excessive intracellular Ca2+ and prevent ROS release. This NPY/Agrp
activation is mediated via ghrelin and stimulates food intake. In parallel,
these neurons present GABAergic inhibitory synapses around POMC
neurons, amplifying the orexigenic signal.
treatment in ob/ob mice results in elevated DHE expression in
POMC neurons. This increase in DHE expression is also found
in POMC neurons of fed wild-type mice compared with fasted
mice, demonstrating a key role of ROS signaling in POMC neu-
rons on the nutritional state. Moreover, the level of ROS in POMC
neurons is correlated with those of leptin in wild-type and ob/ob
mice, but this correlation is lost in HFD-fed mice. In parallel,
the authors noted the presence of peroxisomes in POMC neu-
rons (Diano et al., 2011). Indeed, in POMC neurons from ob/ob
mice, the number of mitochondria and peroxisomes is very low
while it is increased in lean mice. More particularly, mitochon-
dria are outnumbered in lean fed mice compared with lean fasted
mice, without differences in peroxisomes number. On the other
hand, peroxisomes were almost three-fold higher in POMC neu-
rons of HFD fed mice, suggesting a role of this organelle in leptin
resistance and specifically in the disruption of ROS release in
POMC neurons. Hydrogen peroxide icv injection in HFD-fed
mice resulted in increased c-Fos expression in POMC neurons
and decreased feeding in response to peripheral leptin injection.
This spectacular experiment has proved that ROS alone could
reverse POMC function and mediate leptin actions.
Leptin was also shown to be a key molecular actor involved in
synaptic plasticity around POMC neurons (Pinto et al., 2004). In
ob/ob mice, a significantly greater number of excitatory synapses
(EPSCs) on NPY neurons was observed, while the number of
inhibitory synapses (IPSCs) is higher on POMC neurons. After
2 days of intraperitoneal injection of leptin, NPY neurons display
an 85% reduction of the number of EPSCs and an almost 70%
increase in the number of IPSCs. At the same time, there is also
a doubling of the synapses number on POMC neurons, with an
almost 300% increase in the number of EPSCs. This regulation
resembles those of ghrelin on synaptic plasticity (Andrews et al.,
2008), suggesting again an involvement of ROS. Similarly, the
effect of leptin are potentiated by intracellular Ca2+ like ghrelin
(Qiu et al., 2010).
Insulin
In addition to its peripheral effect on glucose storage, insulin
acts on the hypothalamus to modulate energy metabolism and
food intake (Abraham et al., 2014). In particular, insulin inhibits
food intake in the hypothalamus through ROS production. A first
study has demonstrated the key role of the mitochondrial respira-
tory chain in the phosphorylation of insulin receptor on neuronal
cells (Storozhevykh et al., 2007). This study suggests that insulin
might trigger ROS production within the hypothalamus, which,
in turn, inhibit food intake. Indeed, insulin injection in the third
ventricle generates a transient ROS release 15min post-injection
and induces food intake (Jaillard et al., 2009). This insulin-
induced ROS increase is transient because no ROS are observed at
either 5 or 30min post-injection. Moreover, this insulin-induced
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ROS increase is dependent on the nutritional state, because a
decrease of food intake is not observed in fasted mice. The antiox-
idant trolox delivery by icv injection 30min prior to insulin
completely prevents insulin-stimulated ROS increase and sup-
presses insulin-induced food intake inhibition. Interestingly, the
mROS seems to be not involved in this insulin effect. Indeed, icv
injection of an inhibitor of NADPH oxidase (DPI) 30min before
insulin treatment inhibits the effect of insulin on ROS production
and food intake.
CONSEQUENCES OF THE ALTERATION OF HYPOTHALAMIC
ROS RELEASE IN PATHOLOGICAL STATE
The short-term hypothalamic ROS peak generated by metabolic
signals (nutrients and hormones) appears to be fundamental to
elicit a proper behavioral, endocrine and autonomic response
to nutrient intake. A pathology characterized by a disruption in
nutrient sensing and by an inability to maintain energy home-
ostasis is type 2 diabetes (T2D) (Schwartz and Porte, 2005).
T2D is especially characterized by impaired metabolic and hor-
monal hypothalamic sensing, and by a chronic whole-body low-
grade inflammatory background (Purkayastha and Cai, 2013).
An important part of this low-grade inflammation is due to
oxidative stress. As previously described, transient ROS release
is now considered as a molecular signal. When ROS produc-
tion is chronically elevated, the over-abundance of radical species
triggers activation of inflammatory kinases, leading to alter-
ations of tissue functions. This phenomenon is exacerbated by
a decrease in the expression of antioxidant enzymes (Gonzalez-
Chavez et al., 2011). In particular in the brain, this pathological
ROS release induces over-activation of the sympathetic nervous
system (Hirooka et al., 2011). This rise of sympathetic excitation
is responsible for disorders associated with obesity and T2D such
as hypertension, cardiovascular and renal dysfunctions (Campese
et al., 2004), and antioxidant icv injection improves this dele-
terious phenotype. Oxidative stress and inflammation are also
develop in the hypothalamus during T2D (Purkayastha and Cai,
2013).
In this review, transgenic models of obesity or nutritional
models (HFD) mice will be considered as type 2 diabetic mice.
OXIDATIVE STRESS IN THE HYPOTHALAMUS DURING T2D
The different characteristics of T2D suggest an alteration of redox
signaling and ROS release in the hypothalamus. Zücker rats are
obese and insulin resistant with dramatic autonomic disturbances
including modification of sympathovagal balance (York et al.,
1985). In this model, a hypothalamic hypersensitivity to glucose
has been demonstrated (Colombani et al., 2009). In lean rats,
intracarotid injection of low-dose of glucose (3mg/kg) does not
generate ROS release nor a peak of insulin secretion, while a
most important dose of glucose (9mg/kg) induces insulin release
1–3min later associated with hypothalamic mROS production.
This same low-dose of glucose (3mg/kg) is sufficient to pro-
duce a rapid and transient increase in plasma insulin in Zücker
rats. Similarly, low-dose of glucose increases hypothalamic ROS
in Zücker rats. These diabetic rats present an altered redox state,
together with an increase of hypothalamic mitochondrial activity
in response to substrates, and a decrease in antioxidant enzymes
activity. In rats, icv infusion of glutathione for 3 days restores a
normal hypothalamic glucose sensing.
In association with these data, our group has observed that
ROS, and more particularly H2O2 release, is exacerbated in
hypothalamus of HFD-fed mice compared with normal mice
(Duparc et al., 2011a; Drougard et al., 2014). In this study, we
demonstrated that icv injection of high levels of apelin, simi-
lar to that observed in the hypothalamus of obese/diabetic mice
(Reaux-Le Goazigo et al., 2011), in normal mice, induces a
diabetic phenotype with fasting hyperglycemia, fasting hyperin-
sulinemia and glucose intolerance. In fact, these disturbance of
glucose homeostasis via hypothalamic apelin are due to an over-
activation of sympathetic nervous system that triggers hepatic
glucose production. Central apelin effects are directly linked to
hypothalamic over-production of H2O2, since an icv injection
of trolox 30min before apelin icv injection inhibits the estab-
lishment of T2D characteristics. Production of hypothalamic
H2O2 seems to have a mitochondrial origin, since icv injection
of DPI 30min before apelin treatment does not inhibit fasting
hyperglycemia. This high level of hypothalamic H2O2 release
reflects an oxidative stress. Indeed, this release is exacerbated in
hypothalamus of HFD-fed mice in response to apelin, and is
inhibited by trolox pretreatment. Moreover, over-expression of
apelin by lentivectors in the VMH promotes an increase of pro-
inflammatory cytokines expression (Drougard et al., 2014), which
are known to alter the control of metabolism (De Souza et al.,
2005).
ALTERATIONS OF ROS SIGNALING IN POMC AND NPY/AgRP NEURONS
DURING T2D
POMC neurons
Neuronal alterations observed in genetic diabetic mice in
response to glucose are also found in HFD-fed mice (Parton
et al., 2007). Approximately 46% of POMC neurons from lean
mice significantly increase their firing rate after a rise in glucose
concentration from 3 to 5mM compared with HFD-fed mice,
in which only 10% of POMC neurons respond. Moreover, glu-
cose fails to enhance the release of α-MSH in POMC neurons of
HFD-fedmice.We have previously described that POMCneurons
need to release ROS to be effective in response to glucose, and
UCP2 inhibits ROS production. As expected, UCP2 expression is
increased in hypothalamus of HFD-fed mice and genipin treat-
ment restores α-MSH release in response to glucose in POMC
neurons of HFD-fed mice. These results are confirmed by the
protection from obesity, T2D and alteration of glucose sensing
in POMC neurons from UCP2 knock-out mice.
An increase in ROS production in POMC neurons compared
to NPY neurons under “basal” conditions has been observed,
suggesting that POMC neurons might be prone to free radical-
induced degeneration (Andrews et al., 2008). The decline in
functional POMC neurons may promote increased orexigenic
NPY tone, hyperphagia and weight gain. Indeed, ROS levels are
significantly higher in POMC neurons of HFD-fed mice com-
pared to chow-fedmice (Diano et al., 2011). The lack of difference
in ROS levels in POMC neurons between chow-fed mice and
HFD-fed mice is associated with the loss of correlation between
leptin and ROS levels in HFD-fed mice. Indeed, the absence of a
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positive correlation between elevated leptin levels and ROS release
in HFD-fed mice, could be explained by the important rise of
peroxisomes in POMC neurons of these mice. This proliferation
of peroxisome is governed by the nuclear receptor peroxisome
proliferator-activated receptor-γ (PPAR-γ) (Green, 1995) which
is associated with brain inflammation, gliosis (Bernardo and
Minghetti, 2006) and ROS production (Yu et al., 2008). PPAR-
γ expression is increased in hypothalamic POMC and NPY/AgRP
neurons of HFD-fed mice (Diano et al., 2011). These peroxisome
in POMC neurons interfere clearly with ROS signaling, since icv
treatment with a PPAR-γ agonist in normal mice elevates per-
oxisome number, decreases ROS production and increases food
intake. Conversely, icv treatment with a PPAR-γ antagonist in
HFD-fed mice decreases peroxisome number, increases ROS in
POMC neurons and reduces daily food intake. Consistent with
these results, icv treatment with a PPAR-γ antagonist in HFD-fed
mice increases c-Fos staining and firing rate in POMC neurons,
and decreases NPY/AgRP neurons excitation compared withHFD
control mice. As expected, PPAR-γ knock-out mice fed with a
HFD are protected from obesity and T2D (Long et al., 2014).
These mice present a decrease in peroxisomes density in POMC
neurons, which allows ROS signaling and firing rate in these neu-
rons. On a metabolic standpoint, these mice are protected from
hyperphagia, body weight gain, decrease of energy expenditure
and leptin resistance. As previously described, this ROS signal-
ing is overriding in POMC neurons, and icv injection of H2O2
in HFD-fed mice induces c-Fos expression in POMC neurons,
decreases feeding and improves leptin sensitivity in response to
peripheral leptin injection (Diano et al., 2011). It has been shown
that only 3% of POMC neurons from HFD-fed mice are sensi-
tive to leptin, and that H2O2 treatment leads to an 18% increase
of POMC neurons, demonstrating the key role of ROS signaling
from POMC neurons for leptin sensitivity.
NPY/AgRP neurons
NPY/AgRP neurons also seem affected, because if ROS genera-
tion is uncontrolled in these cells, neuronal firing is impaired.
To this aim, emerging concept indicates that T2D is also char-
acterized by ghrelin resistance, since ghrelin fails to induce AgRP
or NPY secretion in hypothalamic explants from HFD-fed mice
(Andrews et al., 2008; Briggs et al., 2010). This global hypotha-
lamic oxidative stress disrupts all the redox balance in POMC,
but also in NPY/AgRP neurons, which alters nutrient sensing and
energy balance. Indeed, insulin, an anorectic hormone, fails to
induce a decrease of food intake in HFD-fed mice, demonstrat-
ing a lack of responsiveness of hypothalamus to peripheral signals
(Storozhevykh et al., 2007).
Mitochondrial dynamics
From the viewpoint of the mitochondrial dynamics, VMH mito-
chondrial fission via DRP1 is essential to respond to glucose
load (Carneiro et al., 2012). Moreover, mitochondrial density
in POMC neurons from HFD-fed mice was increased (Diano
et al., 2011). These mitochondria present a significant reduc-
tion in the number of contacts with ER, indicating that both
mitochondrial network complexity and their association to ER
in POMC neurons are altered in HFD-fed mice (Schneeberger
et al., 2013). The protein involved in mitochondrial fusion pro-
tein Mfn2 seems to be the most crucial protein implicated in
the HFD-fed mice phenotype, since its hypothalamic expres-
sion is decreased in HFD-fed mice when compared to other
mitochondrial fusion/fission proteins such as DRP1 and Mfn1.
Indeed, Mfn2 over-expression in ARC neurons decreases food
intake and body weight, while Mfn2 knock-out mice demon-
strate an increase in food intake and body weight, a decrease of
energy expenditure and a resistance to leptin. These mice also
present an alteration of the mitochondrial respiratory capacity
and an increase in ROS production. This over-production of ROS
appears to be a consequence of hypothalamic ER stress. In fact,
injection of ROS scavenger does not improve the phenotype of
these mice, whereas inhibition of ER stress restores a normal
phenotype.
TREATMENTS AGAINST TYPE 2 DIABETES IN CONNECTION WITH THE
HYPOTHALAMIC ROS
T2D is a worldwide expanding disease that is difficult to treat
because of multiple organ dysfunction. So far, therapies have tar-
geted insulin-sensitive organs such as muscles, liver and adipose
tissue to improve hyperglycemia, hyperinsulinemia and resistance
to insulin (Altaf et al., 2014). However, considerable progress that
have been made in the field of neurophysiology have demon-
strated a key role of the brain, and more particularly the hypotha-
lamus, in the control of energy homeostasis. It is now established
that ROS release in hypothalamic neurons is necessary to gener-
ate the “periphery-hypothalamus-periphery” regulation loop in
response to the nutritional state. This hypothalamic ROS balance
finely regulated could be altered and generate oxidative stress,
which is a disruption of the balance between oxidant and antiox-
idant molecules in favor of oxidant molecules, masking beneficial
effects of ROS (Sies and Cadenas, 1985). The best treatment
against T2D is calorie restriction (Bantle, 1988) to avoid abun-
dance of substrates for mitochondria, and reduce the ROS over-
production. This change in lifestyle is efficient in humans in the
prediabetic state, however patient’s adherence is poor. Regarding
direct targeting of oxidative stress, treatments with antioxidants
could have the potential to prevent or delay the development
of diabetic complications. Despite the preponderance of evi-
dence from animal studies supporting this hypothesis, large scale
prospective studies using antioxidant treatments in humans have
been disappointingly inconclusive, probably because of issues
with dosage and bioavailability of these molecules (Johansen
et al., 2005; Pazdro and Burgess, 2010).
OXIDATIVE STRESS, A LINK BETWEEN T2D AND OTHERS DISEASES
Over-production of ROS (arising either from mitochondrial
electron-transport chain or excessive stimulation of NADPH oxi-
dase) results in oxidative stress, a deleterious process that can
be an important mediator of cell damage. Indeed, hypotha-
lamic oxidative stress during T2D is a risk factor for many
chronic diseases such as neurodegenerative disorders (Valko et al.,
2007). It has been clearly demonstrated that T2D increases the
risk of the development of Alzheimer and Parkinson diseases
via brain oxidative stress (Butterfield et al., 2014; Santiago and
Potashkin, 2014). It is particularly interesting to underlie that
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both neuronal pathologies are characterized by mitochondrial
dysfunctions inducing alteration of brain ROS release.
Given the failure of care therapies against T2D coupled to the
massive expansion of the disease and the associated-pathologies;
it is critical to elaborate integrated therapeutics. Indeed, we have
shown in this review the key role of ROS production in hypotha-
lamus with a different pattern of release between POMC and
NPY/AgRP neurons. ROS signaling is largely altered in T2D, and
the hypothalamus has an “open-access” to bloodstream signals via
the median eminence. Via this anatomical characteristic, it is now
primordial to evaluate the consequences of new therapies on this
hypothalamic balance sensing. Therefore, it will be interesting to
elaborate non-invasive treatments to normalize this hypothala-
mic ROS production via targeting all molecular actors involved
in this ROS release control. To this aim, a study of our group has
demonstrated the alteration of hypothalamic NO release via the
dysfunction of gut-brain axis in response to glucose in db/dbmice
(Duparc et al., 2011b). Modulation of this gut-brain axis could be
an attractive therapeutic strategy to normalize hypothalamic ROS
production.
CONCLUSION
Energy metabolism and food intake are complex processes that
involve homeostatic mechanisms driven by hypothalamic net-
work signaling pathways. This review brings light to the fact that
hypothalamic ROS levels, controlled by various molecules and
fuel signals, play an important role in this hypothalamic con-
trol of energy balance. The control of hypothalamic ROS release
involves many molecular actors such as mitochondrial dynam-
ics, NADPH oxidase activity, synaptic plasticity, peroxisomes,
endoplasmic reticulum,... At high levels that saturate buffering
mechanisms, ROS may initiate cellular degeneration in either
NPY/AgRP or POMC neurons, and impair energy homeostasis,
resulting in pathologies such as obesity and type 2 diabetes. In
addition to the brain, future therapeutic strategies have to take
into account the large part played by ROS signaling in other
structures (including pancreas, adipose tissue, intestine, liver and
heart).
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